Improvement of severe alopecia areata after 9‐month baricitinib treatment followed by subsequent use of upadacitinib in a patient with atopic dermatitis

Uchida, Hideaki; Kamata, Masahiro; Watanabe, Ayu; Itô, Makoto; Fukaya, Saki; Hayashi, Kotaro; Fukuyasu, Atsuko; Tanaka, Takamitsu; Ishikawa, Takeko; Tada, Yayoi

doi:10.1111/1346-8138.16893

Cited by 4 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 Although some of these cases were for the treatment of atopic dermatitis, improvement in the presence of alopecia areata in the patients was also observed. [20][21][22] We reported five patients with diverse backgrounds and varying severity of AA. They had all undergone various conventional therapies before receiving treatment with Upadacitinib, but had not achieved satisfactory results.…”

Section: Discussionmentioning

confidence: 99%

Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series

He,

Yang,

Lai

et al. 2024

CCID

View full text Add to dashboard Cite

Alopecia Areata is a hair disorder influenced by factors such as genetics, immune system, and environmental triggers. The pathogenesis of this condition is still unclear, leading to unsatisfactory current treatments and causing a large number of patients to suffer from it. Janus kinase inhibitors are a new class of drugs that have emerged in recent years and are expected to be promising therapeutic tools for alopecia areata. We report five patients with varying backgrounds and severity of alopecia areata. All of them had received conventional therapy without success. Five patients took Upadacitinib at a dose of 15 mg once daily, and all of them achieved satisfactory efficacy. No adverse events were observed during the treatment of 5 patients.

show abstract